BNP PARIBAS ARBITRAGE/CALL/MODERNA/100/0.01/20.09.24 | Real-time Borsa Italiana 10:06:32 26/06/2024 BST | ||
| 0.376 EUR | -1.05% |
|
| Current month | -10.59% | ||
| 1 month | -40.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 0.376 | -1.05% |
| 25/06/24 | 0.38 | +0.53% |
| 24/06/24 | 0.378 | +8.00% |
| 21/06/24 | 0.35 | -2.23% |
| 20/06/24 | 0.358 | +6.23% |
Real-time Borsa Italiana
Last update June 26, 2024 at 10:06 am
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| P21613 | |
| ISIN | NLBNPIT21613 |
| Date issued | 26/03/2024 |
| Strike | 100 $ |
| Maturity | 20/09/2024 (87 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.66 € |
|---|---|
| Lowest since issue | 0.1405 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.6
USD
Average target price
145.9
USD
Spread / Average Target
+6.00%
- Stock Market
- Warrants
- P21613 Warrant
